Compare LGIH & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | HELP |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 967.4M | 862.2M |
| IPO Year | 2013 | 2020 |
| Metric | LGIH | HELP |
|---|---|---|
| Price | $40.98 | $8.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $41.56 |
| AVG Volume (30 Days) | 378.0K | ★ 1.4M |
| Earning Date | 11-03-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $1,705,504,000.00 | N/A |
| Revenue This Year | $6.07 | N/A |
| Revenue Next Year | $0.89 | N/A |
| P/E Ratio | $18.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.55 | $3.76 |
| 52 Week High | $66.25 | $15.15 |
| Indicator | LGIH | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 38.50 |
| Support Level | $39.20 | $8.20 |
| Resistance Level | $41.50 | $11.74 |
| Average True Range (ATR) | 2.66 | 0.82 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 8.64 | 20.00 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.